Creyos Health has announced the addition of dementia screening, testing, and care planning to its online care platform to enhance how healthcare providers assess and monitor patient cognition.
Supporting the entire dementia care continuum, the protocol has been scientifically validated and backed by one of the largest normative databases in the industry. The protocol evaluates patients for cognitive impairment with efficiency and precision and is the result of 30 years of rigorous research and scientific validation.
It offers full spectrum cognitive care, from early detection of mild cognitive impairment, to testing for an accurate dementia diagnosis, followed by tailored care planning, and ongoing longitudinal monitoring.
Professor Adrian Owen, PhD, OBE, neuroscientist at Western University, and Chief Scientific Officer at Creyos, explained: “Conventional dementia assessments such as the MoCA, SLUMS, or Mini-Cog can identify significant cognitive decline.
“However, they often miss mild cognitive impairment, a critical precursor to dementia. Research has proven that early diagnosis enhances intervention efficacy. With a normative database of 85,000 participants, Creyos is uniquely positioned to deliver a scientifically-validated screening and testing tool.
“Our screener was developed by our in-house science team and its effectiveness has been validated across three distinct populations – healthy individuals, patients experiencing early memory problems, and those with a clinical Alzheimer’s disease diagnosis.
“The result is a screening solution that is both sensitive and specific, and one that will have an immediate positive impact in the communities concerned with brain health.”
The protocol comes on the heels of new statistics released by the Alzheimer’s Association on the prevalence of dementia, indicating that nearly 7 million Americans are living with Alzheimer’s, with that number expected to grow to 13 million by 2050.
The early signs of dementia, such as mild cognitive impairment (MCI) often go unrecognised and, as a result, care that could help improve patient quality of life is delayed. It’s estimated that only 8% of older Americans living with mild cognitive impairment receive an actual diagnosis. With 98 million Americans reaching the age of 65+ by 2060, this gap will grow.
Creyos’s dementia screening, testing, and care planning solution covers the entire spectrum of cognitive care.
This includes:
- Screening for early detection: Creyos’s cognitive screener takes five minutes to complete and accurately identify mild cognitive impairment, a potential early sign of dementia.
- Comprehensive testing: Testing includes four additional tasks and behavioural health questionnaires, aligned with DSM-5 diagnostic criteria for dementia. It automatically tabulates results, reducing time to gather patient information while ensuring greater accuracy.
- Care planning: Digitised templates and readily accessible results and key information allow for the creation of high-quality care plans for every dementia patient without the administrative burden. Providers can generate thorough care plans that include lifestyle advice, medication guidance, and caregiver instructions, all in accordance with Alzheimer’s Association standards.
- Longitudinal monitoring: Creyos’s algorithm creates infinite problem sets resulting in excellent test-retest reliability. With patient performance compared over time and against norms, reports clearly show any changes to help providers understand at-a-glance whether cognitive health has remained stable or is declining, facilitating objective discussions among providers, patients, and caregivers.
“We started Creyos because we noticed a significant gap in how cognitive health was being addressed,” said Marc Lipton, Co-Founder and CEO of Creyos.
“We knew providers needed more objective, efficient, and easily accessible cognitive assessment tools. From day one we’ve collaborated closely with healthcare professionals to continuously enhance our platform to meet their evolving needs, and the needs of their patients. With the increased importance being placed on dementia capture and the growing population impacted by this disease, offering a screening, testing and care planning solution was a natural enhancement to our platform.”
